Lung Cancer – Page 3 – Medical News Asia

Atezolizumab FDA approved for extensive-stage small cell lung cancer (SCLC)

23 March 2019/0 Comments/in US FDA Onc\Haem Approvals, Lung Cancer, Oncology, Chemotherapy, Immunotherapy/by scienterrific

On 18 March 2019, the FDA approved atezolizumab (Tecentriq®, Genentech) plus carboplatin and etoposide as front-line treatment of adult extensive-stage small cell lung cancer (ES-SCLC) patients.

Frontline atezolizumab plus bevacizumab and chemotherapy FDA approved for metastatic non-squamous NSCLC

11 December 2018/0 Comments/in US FDA Onc\Haem Approvals, Lung Cancer, Oncology, Chemotherapy, Immunotherapy, Targeted Therapies/by scienterrific

On 6 December 2018, the FDA approved atezolizumab (Tecentriq®, Roche/Genentech) plus bevacizumab and chemotherapy with paclitaxel and carboplatin for the frontline treatment of metastatic non-squamous non-small cell lung cancer (NSq NSCLC) patients not harbouring any EGFR or ALK genomic tumour aberrations.

Lorlatinib FDA approved for metastatic ALK-positive NSCLC

6 November 2018/0 Comments/in US FDA Onc\Haem Approvals, Lung Cancer, Oncology, Targeted Therapies/by scienterrific

On November 2nd 2018, lorlatinib (LORBRENA®, Pfizer) received accelerated approval by the FDA for the second- and third-line treatment of patients with metastatic, anaplastic lymphoma kinase (ALK)-positive, non-small cell lung cancer (NSCLC). Third-line patients should have had progression on crizotinib and another ALK-inhibitor for metastatic disease, and second-line patients should have had progression on either alectinib or ceritinib in the first-line for metastatic disease.

Pembrolizumab plus chemotherapy approved for metastatic squamous NSCLC

1 November 2018/1 Comment/in US FDA Onc\Haem Approvals, Lung Cancer, Oncology, Chemotherapy, Immunotherapy/by scienterrific

On October 30th 2018, the FDA approved the use of programmed death 1 (PD-1) inhibitor pembrolizumab (Keytruda®, Merck) in combination with carboplatin plus paclitaxel or nab-paclitaxel for the first-line treatment of patients with metastatic squamous non-small cell lung cancer (NSCLC).

Anti-PD1 sintilimab plus biosimilar bevacizumab receive IND-status by China NMPA

15 October 2018/0 Comments/in Medical News Asia, Gastrointestinal Cancer, Lung Cancer, Oncology, Immunotherapy, Targeted Therapies/by scienterrific

SUZHOU, China, Oct. 14, 2018 /PRNewswire/ — The combination therapy of novel programmed death 1 (PD-1) antibody IBI308 (sintilimab, Innovent Biologics) with biosimilar bevacizumab antibody IBI305 (Innovent Biologics) has received the investigational new drug (IND) application for clinical development approval by the National Medical Products Administration (NMPA, formerly known as CFDA) in China.

IMpower133: first-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer

11 October 2018/1 Comment/in Lung Cancer, Oncology, Chemotherapy, Immunotherapy/by scienterrific

Atezolizumab (Tecentriq®, Roche/Genentech) plus standard chemotherapy for the first-line treatment of extensive-stage small-cell lung cancer (SCLC) was associated with a significantly longer overall survival (OS) and progression-free survival (PFS) when compared with chemotherapy alone.

Pembrolizumab plus chemotherapy effective in squamous NSCLC

8 October 2018/2 Comments/in Lung Cancer, Oncology, Chemotherapy, Immunotherapy/by scienterrific

Pembrolizumab (Keytruda®, Merck) in combination with chemotherapy was associated with longer overall survival (OS) and progression-free survival (PFS) when compared to placebo plus chemotherapy in patients with untreated metastatic squamous cell non-small cell lung cancer (NSCLC).

Brigatinib prolongs PFS compared to crizotinib in ALK-Positive NSCLC

5 October 2018/0 Comments/in Lung Cancer, Oncology, Targeted Therapies/by scienterrific

Brigatinib (Alunbrig®, Ariad) significantly prolongs the progression-free survival (PFS) in anaplastic lymphoma kinase (ALK) inhibitor-naïve patients with ALK-rearranged non-small cell lung cancer (NSCLC) when compared to crizotinib, as resulted from the ALTA-1L study.

JAVELIN Lung 200: avelumab vs docetaxel for pretreated NSCLC

2 October 2018/0 Comments/in WCLC 2018, Lung Cancer, Oncology, Immunotherapy/by scienterrific

Avelumab (Bavencio®, Merck KGaA) does not improve the overall survival (OS) in non-small cell lung cancer (NSCLC) patients previously treated with platinum-doublet chemotherapy, as resulted from the JAVELIN Lung 200 study (NCT02395172). The safety profile favoured avelumab over docetaxel.

Dacomitinib FDA approved for the first-line treatment of metastatic EGFR-mutated NSCLC

28 September 2018/0 Comments/in US FDA Onc\Haem Approvals, Lung Cancer, Targeted Therapies/by scienterrific

On September 27, 2018, the FDA approved dacomitinib (Vizimpro®, Pfizer) as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) exon 19 deletions (ex19del) or exon 21 L858R mutations as confirmed by an FDA-approved test.